NEW YORK – Angle this week presented results from an internal feasibility study that integrated its Parsortix cell-sorting platform with BioView's Duet imaging system to improve detection of circulating tumor cells (CTCs) in cancer patients' blood samples.
The group found a higher number of CTCs in metastatic breast, lung, and melanoma cancer patients than previously possible by combining their collection and automated detection platforms.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
